Opinion
Video
Author(s):
The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.
KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition
Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
Cabozantinib Plus Nivolumab Shows Efficacy With/Without Ipilimumab Across Advanced GU Malignancies
Pelabresib/Ruxolitinib Data Underscore Need for Novel End Points in Myelofibrosis Trials
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes